Zevra Therapeutics, Inc. (ZVRA) Covered Calls
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that develops and commercializes innovative therapies for underserved patient populations. Its portfolio includes treatments for Niemann-Pick disease type C and severe endocrine disorders, as well as several late-stage clinical candidates. The company utilizes its proprietary Ligand Activated Technology to optimize drug delivery and therapeutic performance for high-need medical conditions.
You can sell covered calls on Zevra Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ZVRA (prices last updated Fri 4:16 PM ET):
| Zevra Therapeutics, Inc. (ZVRA) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 9.47 | -0.24 | 9.47 | 9.56 | 676K | 7.2 | 0.6 |
| Covered Calls For Zevra Therapeutics, Inc. (ZVRA) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 9 | 0.50 | 9.06 | -0.7% | -31.9% | |
| May 15 | 9 | 0.50 | 9.06 | -0.7% | -7.1% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Zevra Therapeutics focus is on providing life-altering therapies for individuals living with ultra-rare and orphan diseases. Its commercial portfolio is led by products designed to address conditions with few or no existing treatment options. A primary driver of the company current growth is its specialized therapy for Niemann-Pick disease type C, which provides a critical therapeutic pathway for patients suffering from this progressive genetic disorder.
The company also commercializes treatments for severe metabolic and endocrine conditions. By leveraging its proprietary Ligand Activated Technology platform, Zevra creates prodrugs that improve the safety, efficacy, and delivery of established pharmaceutical agents. This approach allows the company to develop differentiated products with enhanced patient compliance and proprietary protection, targeting high-value markets where unmet medical needs remain significant.
Competitive Landscape
The rare disease and orphan drug market is characterized by specialized competition and high barriers to entry. Zevra differentiates itself through its integrated commercial infrastructure and its ability to identify and acquire late-stage assets that complement its existing portfolio. The company competes with both large biotechnology firms and specialized rare disease players for market share and institutional recognition.
- Ultragenyx Pharmaceutical Inc.: A leading biotechnology peer that focuses on the development and commercialization of novel products for rare and ultra-rare genetic diseases.
- ADMA Biologics, Inc.: A peer in the biopharmaceutical space that specializes in the development of plasma-derived biologics for the treatment of immune deficiencies.
- CorMedix Inc.: A competitor focused on developing therapeutic products for the prevention and treatment of life-threatening conditions in healthcare settings.
- Aurinia Pharmaceuticals Inc.: A biopharmaceutical peer that commercializes therapies for autoimmune diseases and severe kidney conditions.
- Agios Pharmaceuticals, Inc.: A leader in the field of cellular metabolism focused on treating genetically defined diseases and hemolytic anemias.
Strategic Outlook and Innovation
The strategic outlook for Zevra Therapeutics is centered on the expansion of its commercial footprint and the advancement of its clinical pipeline. Innovation remains focused on the application of its ligand technology to broader therapeutic areas, including potential treatments for neurological and metabolic disorders. The company is dedicated to enhancing its data-driven approach to patient identification and market access to ensure that its therapies reach the appropriate populations efficiently.
The company continues to seek opportunistic acquisitions and strategic partnerships that align with its focus on rare diseases. By maintaining a disciplined approach to capital allocation and operational efficiency, Zevra aims to build a sustainable and diversified portfolio of commercial assets. The long-term goal is to establish the company as a premier partner for the rare disease community, driving innovation through specialized clinical development and patient-centric commercialization strategies.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | KWEB covered calls | 1. | TVTX covered calls | |
| 2. | SLV covered calls | 7. | TLT covered calls | 2. | VISN covered calls | |
| 3. | EEM covered calls | 8. | TSLA covered calls | 3. | CMPX covered calls | |
| 4. | SPY covered calls | 9. | HYG covered calls | 4. | AXTI covered calls | |
| 5. | QQQ covered calls | 10. | SOFI covered calls | 5. | AAOI covered calls | |
Want more examples? ZUMZ Covered Calls | ZWS Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
